Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients
Watch the video and learn on how to leverage incremental clinical benefit to patients with recent ACS and LDL-C near 70 mg/dL from optimized statin therapy and PCSK9i.
![574543 - Lp(a) and PCSK9 inhibition in nominally controlled LDLC](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-ae/images/image---2023-10-03T200324.861-(1).jpg/jcr:content/image%20-%202023-10-03T200324.861%20(1).jpg)
574543 - Lp(a) and PCSK9 inhibition in nominally controlled LDLC
Related articles
MAT-BH-2200017/v2/Jun 2023